Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (211-220 of 265) with videos related to

Pageof 27
Sort By:
Breast Cancer Research and Treatment|July 29, 2025
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective studyGuido Maria Giuffrè, Luisa Carbognin, Giovanna Masone Iacobucci, et al.
Oncotarget|November 7, 2015
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysisPatrizia Vici, Anna Di Benedetto, Cristiana Ercolani, et al.
Breast (Edinburgh, Scotland)|June 20, 2017
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validationLuisa Carbognin, Isabella Sperduti, Alessandra Fabi, et al.
Journal of Personalized Medicine|August 29, 2024
Outcomes of Radiotherapy in Oligoprogressive Breast CancerFabio Marazzi, Valeria Masiello, Armando Orlandi, et al.
Oncology|December 7, 2021
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, et al.
American Journal of Clinical Oncology|May 22, 2018
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-OncologyFrancesco Pasqualetti, Andrea Pace, Alessandra Gonnelli, et al.
Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.
Acta Oncologica (Stockholm, Sweden)|May 19, 2025
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohortFabio Marazzi, Valeria Masiello, Alessandra Fabi, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
Frontiers in Oncology|October 3, 2022
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trialAndrea Antonuzzo, Carla Ida Ripamonti, Fausto Roila, et al.
Pageof 27

Showing results (211-220 of 265) with videos related to

Sort By:
Pageof 27
Breast Cancer Research and Treatment|July 29, 2025
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective studyGuido Maria Giuffrè, Luisa Carbognin, Giovanna Masone Iacobucci, et al.
Oncotarget|November 7, 2015
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysisPatrizia Vici, Anna Di Benedetto, Cristiana Ercolani, et al.
Breast (Edinburgh, Scotland)|June 20, 2017
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validationLuisa Carbognin, Isabella Sperduti, Alessandra Fabi, et al.
Journal of Personalized Medicine|August 29, 2024
Outcomes of Radiotherapy in Oligoprogressive Breast CancerFabio Marazzi, Valeria Masiello, Armando Orlandi, et al.
Oncology|December 7, 2021
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, et al.
American Journal of Clinical Oncology|May 22, 2018
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-OncologyFrancesco Pasqualetti, Andrea Pace, Alessandra Gonnelli, et al.
Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.
Acta Oncologica (Stockholm, Sweden)|May 19, 2025
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohortFabio Marazzi, Valeria Masiello, Alessandra Fabi, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
Frontiers in Oncology|October 3, 2022
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trialAndrea Antonuzzo, Carla Ida Ripamonti, Fausto Roila, et al.
Pageof 27